O Shaughnessy Asset Management LLC Boosts Stake in Bristol-Myers Squibb (NYSE:BMY)

O Shaughnessy Asset Management LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 613,378 shares of the biopharmaceutical company's stock after purchasing an additional 61,998 shares during the period. O Shaughnessy Asset Management LLC's holdings in Bristol-Myers Squibb were worth $34,693,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Fairway Wealth LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter worth about $28,000. Dunhill Financial LLC lifted its position in shares of Bristol-Myers Squibb by 39.8% in the 3rd quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 189 shares during the period. Comprehensive Financial Planning Inc. PA bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $34,000. Westend Capital Management LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $38,000. Finally, Tacita Capital Inc bought a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $39,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BMY. Cantor Fitzgerald lifted their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Citigroup raised their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Finally, Truist Financial raised their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $57.86.

Remove Ads

Bristol-Myers Squibb Price Performance

BMY stock traded down $0.96 during mid-day trading on Thursday, reaching $58.64. The company's stock had a trading volume of 5,662,034 shares, compared to its average volume of 12,709,407. The stock has a market cap of $119.32 billion, a PE ratio of -13.27, a P/E/G ratio of 2.07 and a beta of 0.43. The company's 50 day moving average is $58.74 and its two-hundred day moving average is $56.54. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.23%. Bristol-Myers Squibb's dividend payout ratio (DPR) is -56.11%.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.